Brugada syndrome.

Area of Science:

• Cardiology
• Genetics
• Electrophysiology

Background:

• Brugada syndrome (BrS) is a novel clinical entity characterized by specific ECG abnormalities and susceptibility to ventricular tachyarrhythmia.
• It presents with ST segment elevation in right precordial leads (V1-V3), right bundle branch block, and risk of sudden cardiac death.
• Prevalence estimates vary, with suggested ranges from 5 to 14 per 1,000 individuals in Caucasian and Japanese populations, respectively.

Purpose of the Study:

• To summarize the key features, inheritance patterns, genetic basis, and management strategies for Brugada syndrome.
• To highlight the importance of identifying high-risk subjects for primary and secondary prophylaxis of cardiac arrest.
• To discuss the role of implantable cardioverter defibrillators (ICDs) and adjunctive therapies like quinidine.

Main Methods:

• Review of clinical entity description, prevalence data, common presentations, and inheritance patterns.
• Discussion of the genetic basis, focusing on SCN5A gene mutations and their role in cardiac sodium channel function.
• Evaluation of therapeutic options, including the efficacy of ICDs and the potential role of quinidine.

Main Results:

• Brugada syndrome is associated with syncope, typically at rest or during sleep, and can lead to ventricular fibrillation and sudden death.
• Autosomal dominant inheritance is suggested, with SCN5A gene mutations accounting for approximately 20% of cases.
• Implantable cardioverter defibrillators (ICDs) are the primary therapeutic option for cardiac arrest prophylaxis.

Conclusions:

• Accurate identification of high-risk individuals is paramount for clinical decision-making in Brugada syndrome.
• Quinidine may serve as an adjunctive therapy for high-risk patients, potentially reducing ICD shocks in those with recurrent events.
• Further research is needed to fully understand the prevalence and optimize management strategies for Brugada syndrome.